Cognos Therapeutics
  • ABOUT
    • MISSION
    • BOARD of DIRECTORS
    • MANAGEMENT TEAM
    • IP MANAGEMENT
    • NEURO-ONCOLOGY BOARD
    • REGULATORY AND COMPLIANCE
  • CLINICAL RELEVANCE
    • FOURTH MODALITY
  • PUBLICATIONS
  • NEWS
  • SHAREHOLDER PORTAL
    • SHAREHOLDER INFORMATION
  • CONTACT
Select Page
Cognos Therapeutics, Inc. To Be Publicly Listed On Nasdaq

Cognos Therapeutics, Inc. To Be Publicly Listed On Nasdaq

by cognosadminteam | Jan 3, 2023 | News

3 JANUARY, 2023 Cognos Therapeutics announced it has finalized a definitive agreement with Nocturne Acquisition Corporation to take the company public on the Nasdaq Stock Exchange. LOS ANGELES, CA. It was announced today on several financial news outlets that Cognos...
Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision

Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision

by cognosadminteam | Nov 2, 2021 | News

2 NOVEMBER, 2021 Co-Founder and CIO Josh Shachar Discusses the Evolution of the Cognos Vision In a recent presentation to the Cognos Shareholders, Josh Shachar, the Co-Founder and Chief Innovation Officer for Cognos Therapeutics presented a compelling vision for the...
Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services

Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services

by cognosadminteam | Nov 1, 2021 | News

Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, including...
Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.

Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.

by cognosadminteam | Oct 28, 2021 | News

28 OCTOBER, 2021 Cognos Announces Addition of New Clean Room To Expand Its Development Capabilities Cognos Therapeutics announced today the addition of an ISO-7 Clean Room to their existing Los Angeles laboratory facility (WATCH THE OVERVIEW VIDEO NOW). The clean...
Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics  as Lead Regulatory Consultant

Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant

by cognosadminteam | Feb 27, 2019 | News

27 FEBRUARY, 2019 Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant Dr. Susan Alpert, MD, PhD, has been named Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory ­­­experts....
« Older Entries

Recent Posts

  • Cognos Therapeutics, Inc. To Be Publicly Listed On Nasdaq
  • Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision
  • Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services
  • Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.
  • Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant

Recent Comments

    Archives

    • January 2023
    • November 2021
    • October 2021
    • February 2019
    • January 2018
    • July 2017
    • September 2016
    • March 2015

    Categories

    • News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Cognos Therapeutics, Inc.

    10604 S La Cienega Blvd.
    Inglewood, CA 90304
    T: 310-641-2700
    F: 310-641-2702
    E: info@cognosthx.com

    ADDITIONAL INFO

    Privacy Policy
    Terms of Use
    • Facebook
    • Twitter
    • Instagram
    • RSS

    Designed by Elegant Themes | Powered by WordPress